Healio: Early data shows new treatment effective for pediatric Hodgkin lymphoma patients
UC expert presents clinical trial data at ASCO conference
A new combination treatment for patients with advanced-stage Hodgkin lymphoma is safe and effective in pediatric patients, according to early new clinical trial data.
Robin E. Norris, MD, associate professor in the University of Cincinnati Department of Pediatrics in the College of Medicine and director of clinical research for oncology and co-director of the young adult oncology program at Cincinnati Children's Hospital Medical Center, presented updated data from an ongoing phase 1/phase 2 clinical trial of a new combination treatment at the American Society of Clinical Oncology Annual Meeting in Chicago last week. The presentation was highlighted in a recent article by Healio.
The trial is studying the effectiveness of a drug called brentuximab vedotin, a combination immunotherapy and chemotherapy agent, with other chemotherapy regimens.
The drug has been FDA approved as a first-line therapy for adults, and the clinical trial has shown safety and effectiveness so far with patients aged 5-18.
“These safety and efficacy data are consistent with those seen in adult patients,” Norris said. “These findings support the use of brentuximab plus AVD as a reasonable option for pediatric patients with newly diagnosed, advanced-stage classical Hodgkin lymphoma."
Featured photo at top of human lymphoma tumor cells courtesy of the National Cancer Institute.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.